Last year we told you that the cell and gene industry would be worth $9 - $14 billion by 2026. We were wrong. According to current market growth rates the industry will surpass $35 billion by 2026 and we want to know how your company is capitalising on this.

New market conditions, lack of established development pathways and constantly evolving global regulatory requirements make the efficient manufacture of cell and gene therapies a challenging undertaking for any company.

We understand that these challenges require industry specific strategies, so we are bringing leading experts from the likes of the MHRA, BlueRock Therapeutics, Orchard Therapeutics, Celyad and Novo Nordisk at this year’s Cell and Gene Therapy Manufacturing Forum, to identify key strategies that will transform your manufacturing capabilities in the move towards commercialisation.